

Business Overview (2009)

ZmTech Scientifique (Scientific) company established in Montreal, Canada in 2008, started up with the expertise services for detecting/ eliminating Mycoplasma contamination in cell cultures, and rapidly expanded with various innovative kits and products, including the Mycoplasma detection/decontamination kits, protein fraction extraction kits, real-time PCR master-mixtures and specific drug polymer cargos, involved in the fields of cell culture, gene/protein expression and analysis, molecular biomarkers and drug delivering. Our aim is to improve experimental efficiency, bio-techniques, clinical assays and the safety, healthy environments in science research, clinic and industry applications.

Currently, a set of newest molecular biomarkers and technologies for breast cancer clinical diagnostic systems were established, to identify and analyze patient's genetic variations and tumor status, which leverage the advantage of rapid, molecular-based microarray (Genechips) and biomathematic technologies, enable to evaluate thousands of genetic markers and rapidly analyze thousands genetic sequences at once, greatly enhance the correction of cancer profiles (early stage: ER+, PR+, Her2- and Lymph node- and prostate) and aid to make a clear decision for prediction, prevention and drug treatments, minimize the potential for over-treatment and under-treatment. The company have the capability to offer laboratories and clinical state-of-the-art, molecular-based assays that provide results in less than 1 week.

Procedure (Zmtech Micro Assay):

1. gene microarray assay:

- Isolation of RNA from FFPE/fresh/frozen tumor tissue
- Fluorescent-labeling of tumor and reference RNA
- Microarray Scanning the Zmtech Micro® microarray

2. gene DASL assays and proteomic assays, included in Zmtech Micro Assays.

- Isolation of RNA and protein from FFPE/fresh/frozen tumor tissue, using Zmtech innovative kits
- Analysis the quantity and quality of isolated RNA and relative protein fractions
- Identify gene profiles with DASL assays and the biomarker protein expression levels with protein assays.

Zmtech Micro assays using the innovative patented biomarkers and powerful microarray technologies, combined with other great discovery tools: DASL, real-time RT-PCR methods and specific protein-probes techniques, would provide more accurate, sensitive, specific, quantitative measures of the breast cancer biological targets and the likelihood of the recurrence risk, enable to guild both doctors and women with breast cancer to determine the most appropriate type of treatments or clinical trails, whether chemotherapy or hormonal therapy alone or combination.